Catabasis Pharmaceuticals

Catabasis Pharmaceuticals
Public
Traded as NASDAQ: CATB
Industry Pharmaceuticals
Headquarters Cambridge, Massachusetts
Key people

Jill C. Milne, Ph.D. (CEO) Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer and Senior Vice President, Clinical Development) Ted Hibben (Chief Business Officer)

Andrew Nichols, Ph.D. (Chief Scientific Officer)
Products Orally-delivered pharmaceuticals
Number of employees
 34 (June 2015)
Website www.catabasis.com

Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.[1] Catabasis’ SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables the company to engineer molecules that simultaneously modulate multiple targets in a disease.[2] Catabasis is applying their SMART linker platform to build an internal pipeline of product candidates for rare diseases and plans to pursue partnerships to develop additional product candidates.

The company made an oral drug, Edasalonexent, which targets Duchenne muscular dystrophy, with plans to begin phase III clinical trials in 2018. The results of phase II clinical trials showed that Edasalonexent had significant effects on muscular enzymes, and prompted the drug to go further into the phase III trial.[3]

References

  1. ↑ "Our Story - Our Company - Catabasis". www.catabasis.com. Retrieved 2017-02-17.
  2. ↑ "Our Technology - Our Technology & Pipeline - Catabasis". www.catabasis.com. Retrieved 2017-02-17.
  3. ↑ "It's Time To Invest In Catabasis Pharmaceuticals Following Impressive Phase 2 DMD Data". Seeking Alpha. 15 February 2018. Retrieved 26 June 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.